Shire (SHPG) Releases FY18 Earnings Guidance
Shire (NASDAQ:SHPG) updated its FY18 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus estimate of $16.02. The company issued revenue guidance of 15.4-15.9 billion, compared to the consensus revenue estimate of $15.47 billion.
Several analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed a buy rating and set a $222.00 price objective on shares of Shire in a report on Wednesday. Sanford C. Bernstein raised shares of Shire from a market perform rating to an outperform rating in a report on Wednesday. Zacks Investment Research raised shares of Shire from a sell rating to a hold rating in a report on Tuesday, February 6th. Royal Bank of Canada set a $192.00 price objective on shares of Shire and gave the stock a buy rating in a report on Monday, February 5th. Finally, Bank of America raised their price objective on shares of Shire from $236.00 to $237.00 and gave the stock a buy rating in a report on Monday, February 5th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $212.50.
Shares of Shire (NASDAQ SHPG) traded up $0.40 during trading on Wednesday, hitting $132.67. 1,187,100 shares of the company were exchanged, compared to its average volume of 1,468,526. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $40,190.00, a price-to-earnings ratio of 25.08, a P/E/G ratio of 0.71 and a beta of 1.41. Shire has a fifty-two week low of $123.73 and a fifty-two week high of $192.15.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.